Investors Target ADMA Biologics in Class Action Over Revenue Claims

The litigation, spearheaded by Levi & Korsinsky, LLP, targets a discrepancy between ADMA’s public disclosures and findings published by Culper Research in March 2026. While ADMA reported a robust $362.5 million in 2025 revenue for its flagship immunoglobulin therapy, ASCENIV, the lawsuit argues these figures were artificially inflated by shipping excess inventory to distributors.

Beyond revenue recognition concerns, the complaint identifies potential conflicts of interest regarding Genesis BioPharma Services. The entity, which operates from ADMA’s corporate headquarters and is allegedly tied to Vice Chairman Jerrold Grossman, was reportedly absent from SEC disclosures as a related party, even as it facilitated product sales. Plaintiffs contend that payors frequently denied or restricted access to ASCENIV due to its high pricing—roughly $900 per gram—yet company reports maintained an image of consistent, high-demand growth. Investors seeking to participate in the recovery effort must file by the August 10, 2026, lead plaintiff deadline.